Urology and China weigh on near-term expectations
17/06/25 -"We have cut our FY2025 EPS estimates to factor in: 1. A softer than expected showing in China, as reflected in the H1 2025 performance 2. Ongoing challenges in Urology, which have been exacerbated by ..."
Pages
66
Language
English
Published on
17/06/25
You may also be interested by these reports :
11/07/25
Given the numerous new product launches, high adoption of existing products, increased presence in point-of-care testing and robust balance sheet, we ...
07/07/25
Sartorius (BUY; Germany), a historically pristine business, has fallen off its perch. Following the big and expensive bet on Polyplus, Sartorius ...
04/07/25
We’ve updated our forecasts to reflect the latest asset disposals, including Baywater (expected to generate €60m revenue in FY24/25 ending June ...
04/07/25
Among Europe’s holding companies, Exor (BUY; Netherlands) is one of the rare, truly active stewards of capital: unafraid to rotate its portfolio, ...